Evidence map›Paper›PMID 34017126›Full record

ArticleNature immunology2021

Author Correction: Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection.

Jianmin Zuo, Alexander C Dowell, Hayden Pearce, Kriti Verma, Heather M Long, Jusnara Begum, Felicity Aiano, Zahin Amin-Chowdhury, Katja Hoschler, Tim Brooks and 14 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Epidemiological assessment of SARS-CoV-2 reinfection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Jianmin Zuo *Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-8341-465X
Alexander C Dowell *Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-1909-7047
Hayden Pearce *Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.ORCID http://orcid.org/0000-0002-8380-8122
Kriti Verma *Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Heather M LongInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Jusnara BegumInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Felicity AianoImmunisation and Countermeasures Division, National Infection Service, London, UK.
Zahin Amin-ChowdhuryImmunisation and Countermeasures Division, National Infection Service, London, UK.
Katja HoschlerImmunisation and Countermeasures Division, National Infection Service, London, UK.
Tim BrooksImmunoassay Laboratory, National Infection Service, Porton Down, UK.
Stephen TaylorImmunoassay Laboratory, National Infection Service, Porton Down, UK.
Jacqueline HewsonImmunoassay Laboratory, National Infection Service, Porton Down, UK.
Bassam HallisImmunoassay Laboratory, National Infection Service, Porton Down, UK.
Lorrain StapleyImmunoassay Laboratory, National Infection Service, Porton Down, UK.
Ray BorrowSero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.ORCID http://orcid.org/0000-0002-0691-6568
Ezra LinleySero-epidemiology Unit, Public Health England, Public Health Laboratory Manchester, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, UK.ORCID http://orcid.org/0000-0002-5935-6154
Shazaad AhmadDepartment of Virology, Manchester Medical Microbiology Partnership, Manchester Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK.
Ben ParkerThe NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK.
Alex HorsleyThe NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester, UK.ORCID http://orcid.org/0000-0003-1828-0058
Gayatri AmirthalingamImmunisation and Countermeasures Division, National Infection Service, London, UK.
Kevin BrownImmunisation and Countermeasures Division, National Infection Service, London, UK.
Mary E RamsayImmunisation and Countermeasures Division, National Infection Service, London, UK.
Shamez LadhaniImmunisation and Countermeasures Division, National Infection Service, London, UK. Shamez.Ladhani@phe.gov.uk.
Paul MossInstitute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. P.Moss@bham.ac.uk.ORCID http://orcid.org/0000-0002-6895-1967

Funding

Bloodwise 17009Medical Research Council MR/V028448/1RCUK | Medical Research Council (MRC) MR/R011230/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34017126
PMCPMC8134969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.